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Introduction
Health care economists estimate that 40-50% 
of annual cost increases can be traced to new 
technologies or the intensifi ed use of old ones 
(Callahan, 2008). However, any limitation of their 
application is massively criticized as unethical. 
Patients (supported by journalists) believe that 
new expensive technology will speed-up their 
treatment and miraculously enhance their 
quality of life, while physicians are fascinated 
by fanciful possibilities of state-of-the-art 
devices. Nevertheless, due to limited resources 
of health care, each particular utilization of 
a medical device should be put to the test of 
the clinical effectiveness and cost-effectiveness 
(Markiewicz, van Til, & Ijzerman, 2014; Rosina et 
al., 2014). The typical approach used above all 
in drugs is to calculate cost-effectiveness when 
the technology is in routine use. Due to special 
properties of medical devices (Rogalewicz & 
Jurickova, 2014), it appears meaningful to start 
with cost-effectiveness analyses already during 
the development and testing phase (Fermont, 
Douw, Vondeling, & Ijzerman, 2016; Tarricone, 
Callea, Ogorevc, & Rupel, 2017).
Health technology assessment (HTA) 
studies can provide healthcare decision makers 
with valuable data concerning effectiveness of 
medical interventions. The main purpose of an 
economic evaluation within HTA may be seen 
in measuring, valuing and comparing the costs 
and consequences of alternatives to support 
economic judgments about an intervention 
or a program. Technological innovations are 
associated with a signifi cant public budget 
impact; hence, a high attention is paid to their 
cost-effectiveness. Cost analyses, the core 
of these studies, require detailed, exact and 
true inputs. In the Central and East Europe 
countries, this is common in drugs, while rather 
disregarded in other technologies including 
medical devices (Gulacsi et al., 2014; Soltes & 
Gavurova, 2014).
This study analyses effectiveness of 
costs of the extracorporeal cardiopulmonary 
resuscitation (ECPR) in relation to the survival 
and quality of life of the patients. The studied 
intervention is regarded as experimental and 
non-standard. Hence, the economic analysis 
can help in decisions about further research 
and assessment of the innovation potential. The 
cost-effectiveness results are assessed from 
the healthcare provider´s perspective under 
different preconditions and for the conventional 
treatment as the comparator. Retrospective 
data from the Department of Acute Cardiology, 
Na Homolce Hospital in Prague (see 
https://www.homolka.cz/en-CZ/about-us.html) 
are used. Two systems for extracorporeal 
membrane oxygenation (ECMO) – Levitronix 
(Thoratec Corporation, USA) and Cardiohelp 
(Maquet, Germany) – are compared. 
1. Background
Outcomes of cardiac arrest have changed 
only modestly despite of modern approaches 
to cardiopulmonary resuscitation (Bednarczyk 
et al., 2014; Fagnoul et al., 2013; Gavurová 
& Vagašová, 2016; Park et al., 2014; Soltes 
& Gavurova, 2015). Extracorporeal life 
support has been recently introduced as 
a therapeutic option for refractory cardiac 
arrest. Resuscitative ECMO was fi rst applied to 
cardiac arrest in 1976 (Mattox & Beall, 1976), 
however, for a long time it was not used due 
to massive complications. Technology progress 
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has led to better outcomes and has facilitated 
widespread utilization of veno-arterial (V-A) 
ECMO (Johnson et al., 2014; Lazzeri et al., 
2013; Lequier & de Caen, 2012). Nevertheless, 
the use of V-A ECMO in the resuscitation of 
adults in cardiac arrest has limited evidence 
(Ken & Alain, 2014; Ostadal et al., 2014), while 
the situation is only little better in neonates and 
children (Huang et al., 2012; Lowry et al., 2013). 
Reports of survival following the ECPR for in-
hospital cardiac arrest in adults range from 
28 to 42% in recent single-site retrospective 
reports (Avalli et al., 2012; Bednarczyk et al., 
2014; Haneya et al., 2012; Kagawa et al., 
2010; Le Guen et al., 2011), and the benefi t 
for out-hospital cardiac arrest patient has been 
discussed and sometimes questioned (Fagnoul 
et al., 2013; Johnson et al., 2014; Kagawa et 
al., 2010; Ken & Alain, 2014). The decision to 
initiate ECMO has become more diffi cult due to 
better availability but remaining uncertainties as 
who might benefi t from it (Ken & Alain, 2014; 
Ostadal et al., 2014; Ramanathan, Cove, Caleb, 
Teoh, & Maclaren, 2015; Sakamoto et al., 
2014). Current guidelines for resuscitation have 
been published by the International Liaison 
Committee on Resuscitation (ILCOR) consisting 
of the American Heart Association (AHA) and 
the European Resuscitation Council (ERC). In 
the Czech Republic, the ERC guidelines are 
observed. The current valid revision is from 
2015 (Truhlar et al., 2015). ECPR should be 
considered as a rescue therapy for the patients 
in whom initial ALS measures are unsuccessful, 
and/or to facilitate specifi c interventions.
As of January 2015, more than 1,600 
patients have received extracorporeal 
cardiopulmonary resuscitation with a 28% 
survival-to-discharge rate worldwide, according 
to the registry of the Extracorporeal Life Support 
Organization (see http://www.elso.org). No 
data from randomized trials exist on ECPR 
as a rescue treatment for cardiac arrest, and 
a randomized trial comparing ECPR with 
conventional cardiopulmonary resuscitation will 
likely never be performed for many reasons, 
including limited sample size, variations in 
regional and institutional practice, or institutional 
unwillingness to randomize patients (Johnson 
et al., 2014; Lowry et al., 2013). Patients 
referred to ECMO during a refractory cardiac 
arrest show nearly 100% mortality without 
this intervention; hence, ECMO represents 
the last chance to survive for them (Ostadal 
et al., 2014). Despite growing evidence from 
retrospective studies demonstrating improved 
survival rate with ECPR in refractory in-hospital 
(Athanasuleas, Buckberg, Allen, Beyersdorf, 
& Kirsh, 2006; Avalli et al., 2012; Bednarczyk 
et al., 2014; Chen et al., 2008; Shin et al., 
2011) and out-hospital cardiac arrest (Chen 
et al., 2006; Johnson et al., 2014; Le Guen et 
al., 2011; Morimura et al., 2011; Nagao et al., 
2010; Sakamoto et al., 2014), a number of 
questions remain unanswered, and data on 
cost-effectiveness of this approach are still 
insuffi cient. Although the intervention is resource 
intensive, cost analyses have been rare (Atsumi 
et al., 2011; Clarke et al., 2014; Lowry et al., 
2013; Mishra et al., 2010; Naess & Steen, 2004; 
Paniagua et al., 2002; Peek et al., 2009; Roos et 
al., 2013; St-Onge, Fan, Mégarbane, Hancock-
Howard, & Coyte; Tseng, Wu, Tsai, Chen, & Lin, 
2011). The aim of this study is a retrospective 
cost-effectiveness analysis performed from the 
provider’s perspective.
2. Methods
The study was designed as a retrospective 
observational comparative study of ECMO 
applied to cardiac arrest in the clinical practice 
of the Na Homolce Hospital in Prague. Records 
of the patient sample were extracted from 
authentic patients´ records; the inclusion 
criteria were the intervention timespan between 
1 January 2009 and 31 March 2014, the 
diagnosis, and the treatment method. The 
basic input diagnosis was (in terms of the 
International Classifi cation of Diseased ICD-10) 
cardiac arrest (I46) and/or cardiogenic shock 
(R570), both conditioned by the refractory 
course, when it was not possible to restore the 
coronary circulation by standard resuscitation 
techniques. Sixteen patients undergoing 
ECPR (all patients undergoing ECPR in the 
Na Homolce Hospital in the particular period) 
were included into the analysis (ECPR group), 
and the data were compared with 35 subjects 
with conventional CPR for refractory cardiac 
arrest (non-ECPR group). The conventional 
methods of CPR involve chest compression 
and artifi cial respiration (in hospitals supported 
by mechanical ventilation), i.e. without applying 
the ECMO system.
Two cost analyses were calculated. First, the 
costs were related to the survival time in a simple 
cost-effectiveness analysis (CEA). Then, 
the quality of life was also taken into account 
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together with the survival time expressing the 
amount of QALYs as their product (Rogalewicz 
& Bartak, 2017; Whitehead & Ali, 2010), 
and a standard cost-utility analysis (CUA) in 
terms of costs per QALY was calculated. The 
health-related quality of life was determined for 
individual Cerebral Performance Categories 
(CPC) by Raina et al. and Stiell et al. (Raina, 
Callaway, Rittenberger, & Holm, 2008; Stiell et 
al., 2003) using the Health Utility Index Mark 3 
(HUI-3) (Whitehead & Ali, 2010).
Mean values of costs were calculated per 
one patient in the respective group for the 
whole hospitalization. They include materials, 
pharmaceuticals, personal costs and overhead 
costs (per a bed and a day) according to the 
respective ward level (coronary care unit, ICU, 
standard ward). Average costs of utilization 
of the ECMO system for one patient including 
consumables are added. The price of the 
ECMO system was calculated on the basis 
of 5-year depreciations.
All prices are given in Czech crowns (CZK) 
and refer to the 2013 price level (with the 
exception of personal costs based on offi cial 
national statistics for 2012 (Maskova, 2013)). 
Although it is not possible to simple recalculate 
prices using the exchange rate due to different 
purchasing power and salary level in different 
countries, for a quick reference one can start 
from the approximate exchange rates CZK/EUR 
= 27.50 and CZK/USD = 24.50 as of beginning 
February 2015 (see http://www.cnb.cz).
It is common in most healthcare systems 
to set a cost-effectiveness (C/E) threshold, 
i.e. the limit costs per QALY for which an 
intervention can be considered cost-effective 
(Rogalewicz & Bartak, 2017). When discussing 
the cost-effectiveness threshold, the limit of 
three times the gross domestic product (GDP) 
per capita recommended by the World Health 
Organization (Rogalewicz & Bartak, 2017; 
WHO, 2002) is often referred to in the Czech 
Republic. According to the 2014 information 
of the Czech Statistical Offi ce, GDP per capita 
was CZK 388,764 in the Czech Republic in 
2013 (the last published results), which gives 




The purchase price of the devices was taken 
from the hospital´s accounting. The price of 
the Cardiohelp system was CZK 2,000,000 
and consumables are delivered in the average 
for CZK 120,000 for one patient. The price 
of the Levitronix system was CZK 600,000. 
Consumables cost CZK 220,000 and it 
is necessary to separately purchase the 
oxygenator for CZK 10,000 and two cannulas 
for CZK 7,000 each. Annual costs of service are 
CZK 23,000 for Levitronix and CZK 2,600 for 
Cardiohelp (in both cases, service for the fi rst 
two years was included in the purchase price). 
Other devices are included in the overhead 
costs per a bed, which is CZK 17,500 per day 
for the coronary care unit, CZK 3,500 per day 
for the (intermediate) ICU, and CZK 1,700 per 
day for a standard bed.
As the hospital did not reveal staff salaries, 
the calculation of personal costs is based on 
national statistical data. Time spent by different 
staff categories were recorded in the hospital 
department, and subsequently multiplied by 
average salaries published by the Institute of 
Health Information and Statistics of the Czech 
Republic for 2012 (latest data published in the 
time of this research) (Maskova, 2013).
The mean total costs for one patient in the 
non-ECPR group were CZK 81,001; Tab. 1 
shows their breakdown. The mean total costs in 
the ECPR group were CZK 788,432 in the case 
of the Cardiohelp system and CZK 885,044 
Cost group Costs (CZK)
Materials, pharmaceuticals 51,660
Personal costs 11,841
Costs per bed: coronary care unit 17,500
Total 81,001
Source: own calculation
Tab. 1: The mean total costs for one patient in the non-ECPR group
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in the case of the Levitronix system. Their 
breakdown is shown in Tab. 2.
3.2 Survival Time CEA
When assessing the clinical effectiveness, 
average survival time was recorded for patients 
from the research sample of patients treated 
in the Department of Acute Cardiology of the 
Na Homolce Hospital. Tab. 3 shows average 
fi gures for the groups of patients with and 
without the ECPR. Clinical parameters are 
recorded for all patients during seven days after 
the cardiac arrest; survival time is monitored 
also after the discharge from the hospital in 
patients that survive. The results suggest that 
the death comes within 12 hours after the 
conventional cardiopulmonary resuscitation 
in the non-ECPR group. Thus, the neurologic 
defi cit value is CPC 5, as all patients eventually 
die. In the ECPR group, eight out of sixteen 
patients survived. Four patients in this number 
reached CPC 1–2 with the average survival 
time of 20 months, and four patients ended 
with CPC 3–4 with the average survival time 
of 5 months. The other eight patients from the 
ECPR group died in average within 10 days, 
although connected to the ECMO system.
The cost-effectiveness ratio (C/E) was 
fi rst calculated taking plain survival time for 
the effect. It resulted in relatively high values 
slightly different for both systems:
C/E (Cardiohelp) = 788,432 / 0.692 = 1,139,353,
C/E (Levitronix) = 885,044 / 0.692 = 1,278,965,
although the costs of non-ECPR patients are 
incomparably lower, the C/E ratio is very high 
due to practically zero survival:
C/E (non-ECPR) = 81,001 / 0.001 = 81,001,000.
Cost group
Costs (CZK)
Cardiohelp system Levitronix system
Materials, pharmaceuticals 408,995 408,995
Personal costs 86,776 86,776
Costs per bed: coronary care unit 129,063 129,063
Costs per bed: ICU 5,950 5,950
Costs per bed: standard ward 3,570 3,570
ECMO system (depreciations + regular service) 20,078 6,690




(number of patients) CPC reached
Average survival time
(in years) (in shorter units)
Non-ECPR (n=35) CPC 5 (100%) 0.001 12 hours
ECPR (n=16) CPC 1-2 (25%) 1.640 1 year and 8 months
CPC 3-4 (25%) 0.410 5 months
CPC 5 (50%) 0.027 9.8 days
ECPR mean value 0.692 8.3 months
Source: own calculation
Tab. 2: The mean total costs for one patient in the ECPR group
Tab. 3: Overview of clinical effectiveness in the course of the cardiopulmonary resuscitation
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These values were combined to get the 
incremental cost-effectiveness ratio (ICER) 
of ECPR towards non-ECPR treatment. 
The resulting ICER is CZK 1,023,778 and 
CZK 1,163,593 for Cardiohelp resp. Levitronix 
ECMO systems. The results of CEA are 
summarized in Tab. 6.
3.3 QALYs and CUA
Health-related quality of life after cardiac arrest 
was evaluated by Stiell and Raina with their 
colleagues, who determined HUI-3 values 
related to CPCs (Raina et al., 2008; Stiell et 
al., 2003). QALYs for individual CPCs were 
evaluated by multiplying their HUI-3 values by 
the mean survival time in our patient sample. 
Resulting QALYs are shown in Tab. 4. The 
average utility for the ECPR group is 0.200 and 
for the non-ECPR group zero. Using the costs 
from Tabs. 1 and 2, we get the incremental cost-
utility ratio (ICUR) for the treatment with ECMO 
compared to the conventional treatment (without 
ECPR). The values are CZK 3,537,155 in the 
case of Cardiohelp, and even CZK 4,020,215 
in the case of Levitronix; both values are high 
above the cost-effectiveness threshold of 
CZK 1,166,292, which speaks against this 
intervention. However, if we calculate ICUR 
for patients with CPC=1–2 only, the results 
are quite different. Tab. 5 shows costs for this 
group of patients (they are higher than the 
mean costs due to better survival leading to 
a longer hospitalization). Taking these costs 
and the utility of 1.312 QALYs into account, we 
get ICUR equal to CZK 772,877 for Cardiohelp, 
and CZK 846 514 for Levitronix. These fi gures 
are already below the C/E threshold. If we were 
able to predict the neurological outcome of the 
intervention, it might lead to a precise selection 
of patients for utilizing ECMO in the case of 
Cost group
Costs (CZK)
(patients with CPC=1–2 only)
Cardiohelp system Levitronix system
Materials, pharmaceuticals 586,009 586,009
Personal costs 139,014 139,014
Costs per bed: coronary care unit 196,875 196,875
Costs per bed: ICU 11,900 11,900
Costs per bed: standard ward 7,140 7,140
ECMO system (depreciations + regular service) 20,078 6,690
ECMO system - consumables 134,000 244,000
Total 1,095,016 1,191,628
Source: own calculation
Tab. 5: The mean total costs for one patient with CPC=1–2 in the ECPR group
CPC and number of patients HUI-3 (Raina et al., 2008; Stiell et al., 2003)
Mean survival time 
[years] QALYs
CPC 1-2 (n=4) 0.8 1.64 1.312
CPC 3-4 (n=4) 0.35 0.41 0.146
CPC 5 (n=8) 0 0.027 0
Weighted average for ECPR 
patients (n=16) 0.29 0.692 0.200
Source: Raina et al. (2008); Stiell et al. (2003)
Tab. 4:
HUI-3 values related to cerebral performance categories (CPC) 
and the respective mean survival times and QALYs for the patient sample 
from the Na Homolce Hospital
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refractory cardiac arrest. In such a case, the 
intervention would be cost-effective. The results 
of CUA are summarized in Tab. 6.
4. Discussion
The results of this retrospective observatory 
study pose several questions. It is obvious that 
utilization of the ECMO system in the refractory 
cardiac arrest gives the patient the last chance 
to be saved. The results from the Na Homolce 
Hospital support the conclusions of published 
studies that utilization of ECMO presents the 
last option in the treatment for the patients 
that, moreover, get into a heavy cardiogenic 
shock after the protracted resuscitation (Avalli 
et al., 2012; Cardarelli, Young, & Griffi th, 2009; 
Chen et al., 2006; Chen et al., 2008; Haneya 
et al., 2012; Kagawa et al., 2010; Le Guen et 
al., 2011; Massetti et al., 2005; Morimura et 
al., 2011; Shin et al., 2011). If the patient is not 
referred for ECMO, the death actually comes in 
100% of cases.
However, when applying ECPR, the survival 
time cannot be taken for a single defi nite predictor 
of the treatment effect, since it does not refl ect the 
actual state of the patient relative to his eventual 
quality of life. In many patients, different degree 
of brain damage appears after a protracted 
cardiopulmonary resuscitation (Atsumi et al., 
2011). Hence, an indicator of the health-related 
quality of life (expressed in QALYs) or of the 
brain damage (in CPCs) is usually used in the 
assessment. In this research, we used CPC 
scores; they are easily convertible to QALYs 
(Raina et al., 2008; Stiell et al., 2003). Hence, 
CPCs allow an easy assessment of quality of life 
in the patients treated and successfully weaned 
from the ECMO system.
In the intensive medicine fi eld, the decision 
about utilization of ECMO is still a clinical 
challenge; the intervention must be adopted 
in a relatively short time, and the decision 
is complicated due to insuffi cient results 
from clinical trials that are heterogenic and 






C/E ratio ECPR (Cardiohelp) 788,432 0.692 1,139,353
ECPR (Levitronix) 855,044 0.692 1,278,965
non-ECPR 81,001 0.001 81,001,000
ICER ECPR (Cardiohelp)
vs. non-ECPR 788,432-81,001 0.692-0.001 1,023,778
ECPR (Levitronix)
vs. non-ECPR 855,044-81,001 0.692-0.001 1,163,593




vs. non-ECPR 788,432-81,001 0.200-0.000 3,537,155
ECPR (Levitronix)





vs. non-ECPR 1,095,016-81,001 1.312-0.000 772,877
ECPR (Levitronix)
vs. non-ECPR 1,191,628-81,001 1.312-0.000 846,514
WHO (2002) recommended C/E threshold (three times GDP per capita) 1,166,292
Source: own calculation
Note: An intervention is considered cost-effective, if the ICUR is below the fi xed C/E threshold; a commonly accepted 
threshold for the Czech Republic is indicated on the last line.
Tab. 6: Results of the cost-effectiveness and the cost-utility analyses
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may give a quite controversial impression 
(Cardarelli et al., 2009). Due to the variability 
in populations studied, differences seem to 
appear based in the geographic composition of 
the respective samples, and also following from 
the differences in national healthcare systems. 
When comparing results of clinical effectiveness 
and cost-effectiveness, almost all European 
studies (Clarke et al., 2014; Hartz et al., 1990; 
Naess & Steen, 2004; Paniagua et al., 2002; 
Plaisance et al., 1999; Raithel et al., 1989) were 
taken into consideration; both clinical and cost 
results obtained in these studies were mutually 
comparable. In the European average, CUA 
is in the region around 23,000 EUR/QALY 
( 632,500 CZK/QALY) (Clarke et al., 2014; 
Mishra et al., 2010; Peek et al., 2009), while 
ICUR (the incremental cost-utility ratio) reaches 
51,315 EUR ( 1,411,000 CZK) (Clarke et 
al., 2014; Roos et al., 2013). These results 
are comparable with those of ours. Greatest 
differences in costs were observed in Asian 
countries. The Japan study (Atsumi et al., 2011) 
suggests CUA in the range of 132,298 EUR/
QALY ( 3,638,000 CZK/QALY), while the 
Taiwan results (Tseng et al., 2011) were 
signifi cantly lower than those from Europe.
In the Czech conditions, ICER for ECPR 
related to the conventional cardiopulmonary 
resuscitation was between CZK 1,023,778 
(Cardiohelp) and CZK 1,163,593 (Levitronix) for 
one year of life. This is on the level of the cost-
effectiveness threshold (CZK 1,166,292). This 
is similar to the results of Clarke et al. (Clarke 
et al., 2014), whose GBP 53,527 per QALY is 
over the threshold applied in England (Devlin 
& Parkin, 2004). Nevertheless, the National 
Health Service (NHS) recommends reimbursing 
ECPR in the case that there is no other option 
to save a human life. However, our results 
suggest that the increased costs of ECMO from 
the healthcare provider´s perspective are cost-
effective above all from the point of view of CUA. 
The ICUR values are between 772,877 CZK/
QALY and 846,514 CZK/QALY for Cardiohelp 
and Levitronix respectively in patients with CPC 
= 1 – 2. These fi gures point at the necessity of 
a good neurological result prediction.
The treatment outcome results in patients 
with the refractory cardiac arrest that appeared 
outside the hospital showed to be less 
favourable (Kagawa et al., 2010). There is 
a delay of the resuscitation due to the distance 
to hospital, which may make the survival chance 
worse. In these patients, the shortest possible 
time until connection to the ECMO system in 
a specialized centre is necessary. The research 
sample is affected by the uniqueness of the 
method that is not widespread in the Czech 
Republic, and thus also patients from outside 
the respective catchment area are included; 
in these patients, the delay in treatment may 
play a signifi cant role in their survival and the 
resulting neurological state.
The natural question appears of which 
patients should receive this therapy. Based 
on the literary review, the criterion could be 
as follows: (1) the age below 75 years, (2) 
the spontaneous circulation is not restored 
within 20 minutes of the enlarged conventional 
cardiopulmonary resuscitation (Ostadal & 
Belohlavek, 2013). Such criteria have also 
an important ethical side, as they decrease 
survival chances above all for older patients 
and also for patients resuscitated in distant 
areas without a specialized cardiocentre with 
the possibility of connecting the patient to the 
ECMO system. The issues of accessibility 
and of an equal access to the intervention that 
often is the last chance of life saving should be 
carefully considered.
Conclusions
Within the Czech healthcare system, ICER 
for ECPR related to the conventional 
cardiopulmonary resuscitation was 
between CZK 1,023,778 (Cardiohelp) and 
CZK 1,163,593 (Levitronix) for one year of 
life. The ICUR values were between 772,877 
CZK/QALY (Cardiohelp) and 846,514 CZK/
QALY (Levitronix) in patients with CPC = 1 – 2. 
These fi gures point at the necessity of a good 
neurological result prediction. Thus, it is much 
more promising for in-hospital than for out-
hospital cardiac arrest patients.
The treatment using the ECMO system is 
more expensive, though, in fact, it is the only 
chance for patients with cardiac arrest for 
a hopeful survival rate and quality of life after 
the intervention. Moreover, it falls below the 
cost-effectiveness threshold (however, it is 
only a supplementary criterion in the Czech 
Republic as well as in many other countries). 
Our data indicate that ECPR for refractory 
cardiac arrest might be cost effective despite 
the high costs per individual patient treated with 
this approach. Larger studies are, however, 
required to confi rm these observations.
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Abstract
COST-EFFECTIVENESS OF EXTRACORPOREAL MEMBRANE OXYGENATION 
IN RESUSCITATION OF PATIENTS WITH REFRACTORY CARDIAC ARREST
Klára Burišková, Vladimír Rogalewicz, Petr Ošťádal
Extracorporeal cardiopulmonary resuscitation (ECPR) has been recently introduced as a therapeutic 
option for refractory cardiac arrest. Despite growing evidence demonstrating improved survival rate, 
a number of questions remains unanswered and data on cost-effectiveness are still insuffi cient. 
The paper is based on a retrospective observational comparative study of authentic clinical data 
from patient records. Incremental cost-effectiveness and cost-utility analyses were performed 
from health care provider’s perspective. Sixteen patients undergoing ECPR were included into 
the analysis and their data were compared with 35 subjects with conventional CPR for refractory 
cardiac arrest. In the ECPR group eight out of sixteen patients were weaned from ECMO, four 
of them with good neurological outcomes (CPC 1-2); three patients survived one year with CPC 
1-2, one patient survived one year with severe neurological dysfunction (CPC 3), and one patient 
with persisting coma (CPC 4). In comparison, in the non-ECPR group all patients died within 24 
hours. In the ECPR group, the average annual costs per patient reached CZK 885,044 (Levitronix 
Centrimag), and CZK 788,432 (Cardiohelp) (the 2013 price level). CUA revealed 3,961,970 CZK/
QALY with Cardiohelp, and 4,447,457 CZK/QALY with Levitronix. However, if only patients with 
CPC 1-2 were included into the analysis, the cost-utility ratio decreased below the unoffi cial Czech 
cost-effectiveness threshold. Our data indicate that ECPR for refractory cardiac arrest may be 
cost-effective despite high costs per individual patients, especially if we were able to better select 
patients for this intervention based on a reliable prediction of the neurological outcome.
Key Words: Cost-effectiveness, cost-utility, extracorporeal cardiopulmonary resuscitation, 
ECPR, refractory cardiac arrest.
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